by Vandana Singh | Oct 1, 2026 | General
Pfizer Inc. (NYSE:PFE) on Thursday presented detailed Phase 2 results for tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis. The ongoing trial met its primary endpoint, showing a statistically significant increase in participants achieving...
by Evette Mitkov | Oct 1, 2026 | General
Unity Software Inc. (NYSE:U) shares are jumping Thursday, moving in sympathy with Accenture after that company posted better-than-expected fourth-quarter results and issued fiscal 2027 sales guidance above analyst estimates. Unity Software stock is showing exceptional...
by Avi Kapoor | Oct 1, 2026 | General
As of Oct. 1, 2026, three stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its...
by Chandrima Sanyal | Oct 1, 2026 | General
U.S. spot Bitcoin ETFs staged a sharp turnaround in the third quarter, attracting $6.34 billion in net inflows after losing roughly $5 billion in the second quarter, according to SoSoValue data. The buying coincided with Bitcoin’s 42.7% quarterly gain, its strongest...
by Vandana Singh | Oct 1, 2026 | General
Agomab Therapeutics NV (NASDAQ:AGMB) reported results from the 48-week open-label extension portion of its Phase 2a STENOVA trial of ontunisertib for fibrostenotic Crohn’s disease. • AgomAb Therapeutics stock is showing notable weakness. Why is AGMB stock dropping?...
Recent Comments